GIDE is a mitochondrial E3 ubiquitin ligase that induces apoptosis and slows growth

Here, we report the identification of GIDE, a mitochondrially located E3 ubiquitin ligase. GIDE contains a C-terminal RING finger domain, which is mostly conserved with those of the lAP family members and is required for GIDE's E3 ligase activity. Overexpression of GIDE induces apoptosis via a pathw...

Full description

Saved in:
Bibliographic Details
Published inCell research Vol. 18; no. 9; pp. 900 - 910
Main Authors Zhang, Bicheng, Huang, Jun, Li, Hong-Liang, Liu, Ting, Wang, Yan-Yi, Waterman, Paul, Mao, Ai-Ping, Xu, Liang-Guo, Zhai, Zhonghe, Liu, Depei, Marrack, Philippa, Shu, Hong-Bing
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.09.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Here, we report the identification of GIDE, a mitochondrially located E3 ubiquitin ligase. GIDE contains a C-terminal RING finger domain, which is mostly conserved with those of the lAP family members and is required for GIDE's E3 ligase activity. Overexpression of GIDE induces apoptosis via a pathway involving activation of caspases, since caspase inhibitors, XIAP and an inactive mutant of caspase-9 block GIDE-induced apoptosis. GIDE also activates JNK, and blockage of JNK activation inhibits GIDE-induced release of cytochrome c and Smac as well as apoptosis, suggesting that JNK activation precedes release of cytochrome c and Smac and is required for GIDE- induced apoptosis. These pro-apoptotic properties of GIDE require its E3 ligase activity. When somewhat over-or underexpressed, GIDE slows or accelerates cell growth, respectively. These pro-apoptotic or growth inhibition effects of GIDE may account for its absence in tumor cells.
Bibliography:Q255
31-1568/Q
GIDE, apoptosis, E3 ligase, mitochondria, caspase, JNK
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These are co-corresponding authors
These are co-first authors
ISSN:1001-0602
1748-7838
DOI:10.1038/cr.2008.75